Loading clinical trials...
Loading clinical trials...
Immune Profiling of COVID-19-infected Patients Admitted to the Intensive Care Unit (ICU): the IMPROVISE Study
Conditions
Interventions
No intervention
Locations
1
Qatar
Hamad Medical Corporation
Doha, Qatar
Start Date
April 27, 2020
Primary Completion Date
June 1, 2022
Completion Date
June 1, 2022
Last Updated
July 16, 2020
NCT06082518
NCT07221162
NCT06631287
NCT06679140
NCT06417762
NCT03830320
Lead Sponsor
Hamad Medical Corporation
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions